...
首页> 外文期刊>Journal of biomedical materials research. Part B, Applied biomaterials. >Biomaterial and antibiotic strategies for peri-implantitis: a review.
【24h】

Biomaterial and antibiotic strategies for peri-implantitis: a review.

机译:Peri-Implantitis的生物材料和抗生素策略:综述。

获取原文
获取原文并翻译 | 示例
           

摘要

Dental implants have 89% plus survival rates at 10-15 years, but peri-implantitis or dental implant infections may be as high as 14%. Peri-implantitis can limit clinical success and impose health and financial burdens to patients and health providers. The pathogenic species associated with periodontitis (e.g., Fusobacterium ssp, A. actinomycetemcomitans, P. gingivalis) are also associated with peri-implantitis. Incidence of peri-implantitis is highest within the first 12 months after implantation, and is higher in patients who smoke or have poor oral health as well as with calcium-phosphate-coated or surface-roughened implants. Biomaterial therapies using fibers, gels, and beads to deliver antibiotics have been used in the treatment of Peri-implantitis though clinical efficacy is not well documented. Guided tissue regeneration membranes (e.g., collagen, poly-lactic/glycolic acid, chitosan, ePTFE) loaded with antimicrobials have shown success in reosseointegrating infected implants in animal models but have not been proven in humans. Experimental approaches include the development of anti-bioadhesion coatings, coating surfaces with antimicrobial agents (e.g., vancomycin, Ag, Zn) or antimicrobial releasing coatings (e.g., calcium phosphate, polylactic acid, chitosan). Future strategies include the development of surfaces that become antibacterial in response to infection, and improvements in the permucosal seal. Research is still needed to identify strategies to prevent bacterial attachment and enhance normal cell/tissue attachment to implant surfaces.
机译:牙科植入物在10-15岁处具有89%加生存率,但腹膜炎或牙科植入物感染可能高达14%。 Peri-Implantitis可以限制临床成功,并对患者和卫生提供者施加健康和金融负担。与牙周炎(例如,Spacterium SSP,A.ActinomycetemcoNIs,P.Gingivalis)相关的病原物种也与Peri-Implantitis有关。在植入后的前12个月内静血炎的发病率最高,吸烟或口腔健康差以及磷酸钙涂层或表面粗糙植入物的患者较高。使用纤维,凝胶和珠子递送抗生素的生物材料疗法已被用于治疗Peri-Implantitis,但临床疗效没有充分记录。引导组织再生膜(例如,胶原,多乳酸/乙醇酸,壳聚糖,壳聚糖,EPTFE)在动物模型中的再塞治疗感染植入物中已经取得了成功,但尚未证明人类。实验方法包括抗生物粘附涂层的发展,具有抗微生物剂的涂层表面(例如,万古霉素,Ag,Zn)或抗微生物释放涂层(例如,磷酸钙,聚乳酸,壳聚糖)。未来的策略包括响应感染而变得抗菌的表面的开发,以及渗透密封的改进。仍然需要研究以确定预防细菌附着并增强对植入表面的正常细胞/组织附着的策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号